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Abstract 
Aim: To compare psychiatric morbidity in treatment-seeking, opioid-dependent patients with 
versus without chronic pain. 
Design: A retrospective comparative cohort design was used involving record linkage from 
routinely-collected, nationally-held datasets.  Data were managed within a Scottish 
Government-certified Safe Haven. 
Setting and participants: Participants comprised all patients of an NHS Substance Misuse 
Service in the East of Scotland (N=521) who were in treatment during the calendar year 2005 
and had been in treatment for varying lengths of time. Their mean age at study inception was 
35.0 years in the chronic pain group and 32.1 years; 32.2% of the chronic pain group and 26.4% 
of the no pain group were female. 
Measurements: The outcomes were a) psychiatric co-morbidity assessed at study inception 
using the 28-item General Health Questionnaire and the Clinical Outcomes in Routine 
Evaluation – Outcome Measure, and b) receipt of at least one prescription for a psychiatric 
condition over a 5-year period following study inception. The independent variable was chronic 
pain measured at study inception using the Brief Pain Inventory – Short Form. 
Findings: 246 (52.7%) reported chronic pain and 221 (47.3%) did not.  A higher proportion of 
patients with chronic pain had at least one psychiatric morbidity (62.4% versus 46.3%, 
p<0.001).  At the study inception a higher proportion of patients with chronic pan were 
prescribed anxiolytics (49.0% versus 39.1%, p=0.015) and antimanic drugs (9.9% compared 
with 4.9%, p=0.015). 
Conclusions: Patients of opioid treatment services in Scotland who report chronic pain may 
have a higher prevalence of psychiatric co-morbidity than those who do not. 
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Introduction 
It is estimated that pain affects up to 80% of opioid-dependent people treated with opioid 
agonist therapy (OAT)1, and severe chronic pain is reported in up to 61%2.  The prevalence of 
psychiatric morbidity is substantial in patients treated in OAT (76%) and, in particular, 
depressive disorders and anxiety disorders3.  Furthermore, the presence of psychiatric 
morbidity and moderate to severe chronic pain can indicate an increased risk of opioid 
dependence in patients exposed to chronic opioid analgesic therapy4,5,6,7.  Additional 
comorbidities can often complicate treatment, including the delivery of psychotropic 
medication and effective analgesia8. 
 
A small number of studies have examined psychiatric morbidity in treatment-seeking, opioid-
dependent patients with and without chronic pain.  They found that the presence of chronic 
pain was associated with a higher prevalence of depressive disorders9, anxiety disorders10 or 
both11.  Barry and colleagues12 examined a range of psychiatric morbidities in 150 methadone-
maintained patients, divided into three groups: chronic severe pain (CSP) lasting at least 6 
months; some pain (SP) in the past week; and no pain (NP).  They found that, compared with 
the NP group, both the CSP and the SP groups demonstrated a significantly higher prevalence 
of depression, somatization and anxiety, along with significantly higher Global Severity Index 
(GSI) scores.  Furthermore, the CSP group was found to have a significantly higher prevalence 
of somatization and significantly higher GSI scores than the SP group. 
 
Patients with chronic pain and coexisting opioid dependence disorders present with complex 
illnesses that are difficult to treat together effectively.  Psychiatric morbidity is prevalent in 
both of these conditions and further compounds the complexities impacting on treatment.  The 
development of effective treatment strategies for patients with chronic pain and coexisting 
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opioid dependence is dependent upon also understanding the prevalence and pattern of 
psychiatric morbidity in this clinical population. 
 
Aims and objectives 
Based on the findings of the previous studies noted above, our main hypothesis was that OAT 
patients with chronic pain, compared with those with no pain, would have a higher prevalence 
of psychiatric morbidity.  We also hypothesised that there would be group differences 
concerning psychotropic prescribing; however, the direction of these differences could not be 
anticipated by prior evidence. 
 
The aim of the present study was therefore to compare psychiatric morbidity (and, specifically, 
depressive disorders, anxiety disorders and bipolar disorder) in treatment-seeking, opioid-
dependent patients with and without chronic pain who were attending a substance misuse 
service in the East of Scotland. The specific study objectives were: 
1) To compare sociodemographic characteristics by group (i.e. those with chronic pain 
versus those with no pain); 
2) To compare the proportion of each group meeting clinical thresholds for general 
psychiatric morbidity (using both the GHQ-28 and CORE-OM), and to compare 
subscale scores derived from both instruments at study inception; 
3) To examine rates of psychotropic drug prescribing (antidepressants, anxiolytics and 
antimanics) at study inception and during the 5-year follow-up period, and to compare 
these between groups. 
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Our rationale was to either substantiate, or challenge the currently limited evidence base in this 
area of study, thereby improving our understanding of the cluster of opioid dependence, chronic 
pain and general psychiatric morbidity. 
 
Previous work 
In a recent publication13, by the authors of the present study, illicit drug use was described in 
these two groups, using the same clinical population.  This previous study reported that, 
compared with those with no pain, a significantly higher proportion of those with chronic pain 
were engaged in abuse of benzodiazepines and cannabinoids, both at study inception and 
during the 5-year follow-up period. 
 
Methods 
Design 
The present cohort study employed the use of a health informatics approach to link and 
interrogate routinely-collected data held by the Scottish Government.  This was considered the 
most cost-effective means of responding to the research aim of the present study.  The study 
inception data were collected during the calendar year 2005, and 5-year follow-up data spanned 
2005-2010.  The protocol was developed in 2016 and took advantage of a service audit that 
had been undertaken during the calendar year 2005, as detailed above.  The present study also 
took advantage of the historical nature of the Scottish-Government health datasets, to ensure 
that an accurate 5-year observation period was included for each participant. 
 
These data are now several years old; however, the relevance of the findings is likely to apply 
in many current contexts.  The increase in opioid analgesic prescribing, generally considered 
to have contributed to the ‘opioid crisis’ was witnessed in the UK14; however, the 
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corresponding rise in drug-related death, which began to emerge in the US around 2009, was 
not witnessed in the UK15.  Whilst there is a literature suggesting cautionary lessons, which 
could be extrapolated from US data, the ‘opioid crisis’ has had little impact on prescribing 
practices in the UK to date, and current papers continue to call for policy changes aimed at 
reducing high-dose prescribing practices14. 
 
Participants 
Participants comprised all methadone-maintained patients attending a National Health Service 
(NHS) substance misuse service in the East of Scotland, UK.  Overall, relative to Scotland, this 
Health Board is generally characterized by high socioeconomic deprivation and relatively poor 
health.  The Scottish Office for National Statistics (ONS) has reported this as a consistent 
finding for the past several decades.  All participants were clinically-diagnosed as being 
dependent upon opioids – primarily heroin – on entry to treatment, and many were also engaged 
in polysubstance abuse.  A case-control design was employed: cases were treatment-seeking, 
opioid-dependent patients with comorbid chronic pain and controls were treatment-seeking, 
opioid-dependent patients with no pain.  In previous studies, three temporal thresholds have 
been established to identify chronic pain: 3 months; 6 months; and 12 months16.  In the present 
study the chronicity threshold was set at 12 months; the rationale for employing this threshold 
was that, in a clinical population familiar with persistent, debilitating conditions, the highest 
conventional threshold was considered to facilitate the best comparison between truly ‘chronic’ 
pain and no pain.  Patients reporting pain that had been present for less than 12 months were 
excluded, since these patients may not have formed a sufficiently-homogenous group to justify 
inclusion in the present study. 
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Materials 
A service-modified version of the 9-item Brief Pain Inventory – Short Form (BPI-SF)17 was 
designed to assess the sensory and reactive dimensions of pain.  The BPI-SF has been validated 
in a number of clinical populations, including patients in receipt of methadone maintenance 
therapy for the treatment of opioid dependence18. 
 
The 28-item version of the General Health Questionnaire (GHQ-28)19 was designed as a 
screening tool to indicate psychiatric diagnostic status.  The GHQ scoring method was used 
and a threshold of23/24 was applied to indicate clinical status.  It has been shown to have the 
ability to accurately detect diagnoses in accordance with the Composite International 
Diagnostic Interview (CIDI)20.  The reliability and validity of the GHQ-28 is well-documented 
in numerous clinical populations12-25.  Whilst acceptable levels of reliability and validity have 
been demonstrated for the GHQ-60 in substance misusers26, the psychometric properties of the 
GHQ-28 have not yet been assessed in opioid-dependent clinical populations. 
 
The 34-item Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM)27 
assesses the level of current psychological global distress.  A threshold of ≥34 was used to 
indicate clinical status28.  It has been validated in samples from the general population and in 
clinical samples27,29.  Its validity is yet to be assessed in opioid-dependent populations, and the 
CORE-OM is yet to be compared with ‘gold standard’ diagnostic instruments, such as the 
Composite International Diagnostic Interview (CIDI); however, it is shown to have a strong 
positive correlation (0.75) with the GHQ30. 
 
An electronic regional extract of the nationally-held prescribing data was obtained from the 
Prescribing Information System (PIS), National Services Scotland (NSS).  These data include 
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a record of every prescription dispensed. Within this dataset exists a field documenting the 
clinical indication for which the medication was prescribed, recorded as British National 
Formulary (BNF) sub-section codes.  Prescribing data relating to individuals are identified by 
a person-specific unique code, the Community Health Index (CHI) number, which is held by 
every individual registered with the NHS in Scotland.  The CHI number is also included in 
every record of every NHS transaction, and can be used for linkage of data between services. 
 
Procedure 
The study was incepted on 1 January 2005, and the BPI-SF, GHQ-28 and CORE-OM were 
completed at routine weekly clinic appointments, with specialist addiction nurses, for each 
participant at an arbitrary point during that calendar year.  Time spent in treatment prior to 
study inception was unknown for study participants.  Five-year follow-up prescribing data were 
obtained spanning 01/01/05-12/12/10.  The BNF codes used to identify anxiety disorders, 
depression and bipolar disorder were: ‘4.1.2 Anxiolytics’; ‘4.3 Antidepressant drugs’; and 
‘4.2.3 Drugs for mania and hypomania’.  It should be noted that the patient population in receipt 
of drugs for mania and hypomania is likely to be relatively heterogeneous since these 
medications includes anticonvulsants, lithium and antipsychotic medication.  Without extreme 
rigour in this process, misclassification could result in a spuriously higher prevalence of bipolar 
disorder.  [BNF can be accessed at http://gmmmg.nhs.uk/html/formulary_bnf_chapters.html]  
Prescribing was used as a proxy indicator of clinically-significant psychiatric morbidity; 
however, it should be noted that this does not include patients with psychiatric morbidity being 
treated solely with non-pharmaceutical interventions.  Participants were excluded from the 
study if no BPI-SF was completed or if duration of pain at study inception was not recorded, 
since it was not possible to determine if their pain was ‘chronic’. 
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Data from study inception were transferred to the Health Informatics Centre (HIC) Services, 
one of the Scottish government-certified electronic Safe Havens, based at the University of 
Dundee.  These data were then linked within a secure virtual environment, using the CHI 
numbers, and anonymized prior to release to the research team for analysis via a secure web 
link. 
 
Terminology 
The term, ‘psychiatric morbidity’ is used throughout the present manuscript, for consistency 
and clarity; however, it should be noted that the GHQ-28 and CORE-OM subscales are not 
designed to assess clinical status concerning specific psychiatric morbidities, but rather to 
assess overall symptom severity. 
 
Statistical considerations 
The Statistical Package for Social Scientists (SPSS v22) was used to undertake statistical 
testing.  Chi square testing was used in all examinations of group associations where both the 
dependent and independent variables were categorical (i.e. nominal). This included analyses 
by: gender; deprivation status; presence of psychiatric morbidity; and receipt of prescription 
drugs.  Comparison of the proportions of each group in receipt of prescribed medication at 
study inception and 5-year follow-up was also undertaken using Chi square testing since 
repeated measures analyses of these binary outcomes for individuals (in receipt or not in 
receipt of medication) was not regarded as clinically meaningful.  Descriptive summary data 
are presented as number of events (n) and percentage of group (%), and the p-value is 
reported. 
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Univariate analysis of variance (ANOVA) was used in all examinations of group differences 
where the dependent variables were continuous and the independent variables were categorical 
(i.e. nominal). This included analyses by age, GHQ-28 subscales and CORE-OM subscales.  
Descriptive summary data are presented as mean value (
_
x ) and standard deviation around the 
mean (σ), and the p-value is reported. 
 
Repeated measures ANOVA was used to assess group changes over time in the mean number 
of prescriptions dispensed each year during the observation period.  Repeated measures 
ANOVA statistics are reported in the same way as univariate ANOVA findings.  In addition, 
the repeated measures ANOVA computes: main effect of group (overall group differences 
during the entire observation period); main effect of time (changes over time in the entire 
treatment population irrespective of group); and the interaction effect (between group and 
time).  Sphericity exists in ANOVA testing when the variance of the difference between all 
possible pairs of within-subject conditions are equal.  The violation of sphericity results in an 
increase in the Type I error rate (i.e. false positive results).  The Mauchley Sphericity Test was 
used to identify violations of sphericity and, where present, to identify the appropriate method 
of adjustment.  A Bonferroni correction was applied in the repeated measures ANOVA 
procedure to compensate for multiple comparisons.  As a result of the small number of 
participants available for repeated measures analyses (i.e. the number prescribed medication 
during each of the 5 years in the observation period), participants were included in the graphs 
on the right side of each figure if they received relevant prescribed medication at any point 
during the observation period. 
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Ethical approval 
Ethical approval was not required for the present study, since all data were anonymized and 
accessed via a national Safe Haven; however, a favorable ethical opinion was obtained from 
the East of Scotland Research Ethics Committee (EoSREC). 
 
Results 
The study sample after exclusions was demographically similar to the cohort before 
exclusions13, and the reasons for exclusion are also reported in this previous manuscript.  Table 
1 shows the sociodemographic characteristics of the chronic pain (CP) group and the no pain 
(NoP) group. 
 
Indications of psychiatric morbidity in patients with and without chronic pain at study 
inception (assessed using the GHQ-28 and the CORE-OM) 
The proportion of each group meeting clinical thresholds, and the subscale scores on the GHQ-
28 and the CORE-OM are shown in Table 2. 
 
Table 2 shows that a significantly higher proportion of people in the CP group were identified 
as having psychiatric morbidity compared with the NoP group, using both the GHQ-28 and the 
CORE-OM assessment instruments.  It further shows that the CP group had significantly higher 
mean scores on all of the GHQ-28 and CORE-OM subscales. 
 
Prescribing characteristics indicative of clinically-significant psychiatric morbidity during the 
5-year follow-up period 
Figures 1 to 3 show the proportion of participants in receipt of the psychotropic medication at 
any point during each of the years during the observation period (on the left of each figure) and 
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the mean number of prescriptions dispensed during each of these years (on the right of each 
figure).  The statistics from the repeated measures ANOVA are shown in Table 3. 
 
Figure 1 shows that a significantly higher proportion of the CP group was prescribed 
anxiolytics at inception (χ2(1)=5.090; p=0.015; ω=0.104); however, there was no group 
difference at 5-year follow-up.  Table 3 shows that the CP group was in receipt of a higher 
overall mean number of anxiolytic prescriptions per person during the observation period.  
There was a main effect of time, whereby the mean number of prescriptions decreased over 
time, and pairwise comparison determined a significant difference between 2005 and 2007 (-
1.93; p=0.001), between 2005 and 2008 (-1.88; p=0.002), between 2005 and 2009 (-2.20; 
p<0.001) and between 2005 and 2010 (-2.37; p<0.001).  There were no other differences on 
pairwise comparison. 
 
Figure 2 shows that the proportion of each group in receipt of prescribed antidepressant drugs 
was relatively similar; there was no significant group difference at study inception or at 5-year 
follow-up.  Table 3 shows no overall effect of group or time.  There was a significant 
interaction effect between group and time.  Whilst the mean number of prescriptions remained 
relatively consistent over time in the CP group (4.99 mean prescriptions per person in 2005 
and 5.14 mean prescriptions per person in 2010), there was a steady increase in the number 
within the NoP group (ranging from 2.99 in 2005 to 4.87 in 2010). 
 
Figure 3 shows that a significantly higher proportion of the CP group was in receipt of 
prescribed antimanic drugs at study inception (χ2(1)=5.337; p=0.015; ω=0.107); however, there 
was no significant group difference at 5-year follow-up.  Table 3 shows that there was a 
significant main effect of time.  Pairwise comparison revealed a significant difference between 
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2005 and 2009 (+3.26; p=0.002) and between 2005 and 2010 (+4.13; p<0.001).  There was no 
significant interaction effect between group and time. 
 
Discussion 
This study aimed to compare psychiatric morbidity (and, specifically, depressive disorders, 
anxiety disorders and bipolar disorder) in treatment-seeking, opioid-dependent patients with 
and without chronic pain.  At study inception, based on the GHQ-28 and the CORE-OM, a 
significantly higher proportion of the chronic pain group reported higher anxiety- and mood-
related symptom severity, poorer overall wellbeing and life functioning, and increased risk of 
harm.  During the observation period, a significantly higher proportion of the chronic pain 
group was in receipt of prescribed medication for the treatment of anxiety disorders and bipolar 
disorder but, despite a higher proportion reporting mood-related symptoms, there was no 
significant group difference in prescription drugs used to treat depressive disorders. 
 
Higher prevalence of depressive symptoms in the chronic pain group is consistent with the 
findings of other studies9,11,12,31.  Jamison and colleagues2 reported that antidepressant 
medication was prescribed to 28% of the chronic pain group compared with 15% of 
methadone-maintained patients with no pain.  These figures are lower than the findings of the 
present study, where substantially more than a third of each group was prescribed 
antidepressant medication at any point during the observation period.  The disparity in findings 
between the studies may reflect ease of access to treatment in these two populations.  Jamison 
and colleagues undertook their study in a US population and indicated that almost three 
quarters of their study cohort were in receipt of financial aid (and, presumably, eligible for 
Medicaid/Medicare), whereas, the present cohort utilized NHS treatment resources in the UK.  
Prior authorization and financial reimbursement requirements associated with US 
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governmental health insurance may mean that access to specific treatments is limited compared 
with NHS treatment access in the UK.  The higher prevalence of depressive symptoms in those 
with chronic pain and the absence of group differences concerning receipt of prescription drugs 
for the treatment of depression may reflect unrecognized psychiatric morbidity, particularly in 
the chronic pain group and, again, highlights the importance of psychiatric assessment in 
clinical populations at risk of psychiatric morbidity. 
 
The relatively high prevalence of treatment for bipolar disorder in the chronic pain group may 
reflect the more ‘chaotic’ symptoms associated with this condition32.  Bipolar disorder and 
chronic pain are common comorbidities33,34,35, and substance dependence in patients with 
bipolar disorder is associated with a desire to manage the emotional and behavioral extremes 
that characterize this disorder36.  Faced with pre-exisitng substance misuse, clinicians are likely 
to find pain management difficult to achieve due to the risk of exacerbating substance misuse 
problems.  Effective treatment of this dynamic comorbidity cluster necessitates collaborative 
approaches between addiction psychiatrists, general psychiatrists and pain specialists. 
 
The significantly higher prevalence of anxiety-related symptoms in the chronic pain group is 
consistent with the findings of other studies9,11,12,31.  Given the high prevalence of anxiety-
related symptoms in the present cohort (based on the GHQ-28 and the CORE-OM) – 
particularly in the chronic pain group – and the relatively small proportion in receipt of 
anxiolytic treatment, this may indicate undertreatment of anxiety in both groups.  This may 
reflect a patient reluctance to seek help for psychological distress.  Indeed, it has been suggested 
that patients with chronic pain often minimize their psychological distress, fearing that their 
pain symptoms may be dismissed as mental disorders37.  It is not only patients with pain who 
minimize the role of psychological distress, however, but also clinicians and policymakers who 
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oppose opioid use for chronic pain management on the basis of individual harms such as 
dependence or abuse. 
 
Potential undertreatment of anxiety may be associated with the substantial illicit 
benzodiazepine use reported previously in both groups13.  Persistent and debilitating pain can 
exacerbate ongoing anxiety or can induce pain-related anxiety or pain catastrophisation38.  This 
is a dynamic relationship which can, eventually, exacerbate both pain and anxiety in patients39.  
There was, however, a reduction in the proportion of each group treated with anxiolytics during 
the follow-up period, but particularly in the chronic pain group.  These reductions may be 
driven by concern for patients since benzodiazepines are known to enhance the euphoric effect 
of opioids and may potentiate substance misuse40; and inhibition of cytochrome P450 can lead 
to decreased clearance of these drugs, thereby increasing risk of overdose, respiratory 
depression and accidental death40,41.  This renders general psychiatric intervention of key 
importance in ensuring that benzodiazepine requirements are recognized, and consumption is 
controlled and monitored. 
 
The finding that psychiatric morbidity is more prevalent – rather than less prevalent – in those 
with chronic pain, is important in understanding the patient pathways into substance use 
disorders.  Effective pain management could reduce the prevalence of psychiatric morbidity in 
this dynamic morbidity cluster and could potentially result a reduction in substance misuse in 
these patients. 
 
Limitations 
A key limitation of this study is that psychiatric assessment instruments were used at study 
inception only.  Whilst psychiatric morbidity is generally chronic, this may have resulted in a 
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degree of misclassification during the observation period, since some patients may have 
developed psychiatric morbidity and, indeed, some may have recovered.  It should be noted 
that, when comparing psychiatric assessments (which were undertaken at study inception only) 
with psychiatric prescribing, any evidence of undertreatment may be a result of recovery.  
Furthermore, it should be noted that the GHQ-28 and CORE-OM were not designed to be used 
as diagnostic instruments; however, the GHQ-28 is shown to to have the ability to accurately 
detect diagnoses in accordance with the CIDI20. 
 
A further limitation is the use of prescribed medication to indicate psychiatric morbidity; 
however, it is likely to indicate relatively severe and chronic psychopathology.  This may also 
have resulted in a degree of misclassification since this would not have included those that 
were treated solely using non-pharmacological interventions. 
 
Additionally, the process of assigning BNF codes in the prescribing dataset has not undergone 
psychometric assessment.  This particular technique for identifying clinical diagnoses could be 
strengthened by validation of the BNF code selection process used in that particular data field. 
 
Finally, the present study was unable to consider the role of patient pathways to substance 
abuse, and this may be an important consideration when examining differences between 
patients with chronic pain and with no pain.  There is a need of further work in this area, 
identifying initial exposure (prescription opioids or ‘street’ opioids) and examining the impact 
that this route of exposure has on treatment outcomes. 
 
 
 
 
 
This article is protected by copyright. All rights reserved. 
Conclusions 
There is a high prevalence of psychiatric morbidity – specifically mood- and anxiety-related 
disorders – in opioid-dependent patients, particularly those with chronic pain; however, not all 
patients who exhibit psychiatric morbidity are treated with medication.  General psychiatric 
intervention, in collaboration with addiction psychiatrists, may assume a pivotal role in 
addressing the complex and challenging health problems in these clinical populations. 
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Table 1: Group comparison of sociodemographic characteristics at study inception. 
 
   
N 
 
% 
 
N 
 
% 
 
  
Male 155 68 148 74 0.120 
  
Socioeconomic deprivation †  0.087 
 SIMD Quintile 1 163 68 124 58  
 SIMD Quintile 2 59 24 60 28  
 SIMD Quintile 3 13 5 18 8  
 SIMD Quintile 2 2 1 8 4  
 SIMD Quintile 5 5 2 4 2  
  
Geographical area  0.396 
 Angus 49 22 54 27  
 Dundee 171 75 139 69  
 Perth & Kinross 8 3 8 4  
  
Urban-rurality  0.460 
 Large urban areas 176 73 147 69  
 Other urban areas 46 19 49 23  
 Accessible small towns 9 4 13 6  
 Remote small towns 1 1 0 0  
 Accessible rural 7 3 4 2  
 Remote rural      
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        CP       NoP p-value 
  _
x  
 
σ 
_
x  
 
σ 
 
  
Age (years) 34.97 7.49 32.10 7.86 <0.001 
  
† The Scottish Index of Multiple deprivation was used in assessing socioeconomic deprivation, whereby, quintile 
1 represents the greatest deprivation and quintile 5 represents the greatest affluence. 
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Table 2: Indicators of psychiatric morbidity at study inception: clinical thresholds and 
subscale scores on the GHQ-28 and the CORE-OM 
        CP     NoP p-value 
  N % N %  
  
Above ‘clinical’ threshold [GHQ-28] 126 62 84 46 0.001 
  
Above ‘clinical’ threshold [CORE-OM] 175 74 127 58 <0.001 
  
Subscales        CP      NoP p-value 
 _
x  
 
σ 
_
x  
 
σ 
 
  
GHQ-28: Social Dysfunction 8.27 3.24 7.62 2.95 0.026 
GHQ-28: Somatic Symptoms 8.03 3.83 5.87 3.52 <0.001 
GHQ-28: Anxiety/Insomnia 8.81 4.86 7.22 4.38 <0.001 
GHQ-28: Severe Depression 5.07 4.87 4.03 4.09 0.015 
CORE-OM: Subjective Wellbeing 7.39 4.48 6.47 3.85 0.020 
CORE-OM: Problems/Symptoms 25.68 17.44 18.66 10.68 <0.001 
CORE-OM: Life Functioning 18.94 11.88 15.90 9.47 0.003 
CORE-OM: Risk/Harm 2.55 3.67 1.83 3.07 0.024 
NOTES: The range of the GHQ-28 subscales is 0-21; the range of the CORE subjective wellbeing subscale score 
is 0-16; the range of the CORE problems/symptoms and life functioning subscale scores is 0-48; the range of the 
CORE risk/harm subscale score is 0-24. The Subjective Wellbeing and Life Functioning CORE subscales are 
negatively scored, therefore, a higher score is indicative of greater symptom severity. 
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Table 3: Overview of findings of repeated measures ANOVA examining the number of 
anxiolytic, antidepressant and antimanic prescriptions dispensed during the 5-year follow-up 
period 
  Direction Mean difference p-value 
     
Anxiolytics    
 
 
Overall effect of group 
 
CP ↑ / NoP ↓ 
 
+1.53 prescriptions 
0.025 
 Overall effect of time Decrease Described in text <0.001 
 Interaction effect ---------------- ---------------- NS 
     
Antidepressants    
 Overall effect of group ---------------- ---------------- NS 
 Overall effect of time ---------------- ---------------- NS 
 Interaction effect Described in text Described in text 0.012 
     
Antimanics    
 Overall effect of group ---------------- ---------------- NS 
 Overall effect of time Increase Described in text <0.001 
 Interaction effect ---------------- ---------------- NS 
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Figure 1: Percentage of the cohort prescribed anxiolytics (n=168; 36% of the cohort), and 
the mean number of prescriptions dispensed per patient per annum during the 5-year follow-
up period.  Error bars indicate standard error. 
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Figure 2: Percentage of the cohort prescribed antidepressant drugs (n=307; 66% of the 
cohort), and the mean number of prescriptions dispensed per patient per annum during the 5-
year follow-up period.  Error bars indicate standard error. 
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Figure 3: Percentage of the cohort prescribed antimanic drugs (n=65; 14% of the cohort), 
and the mean number of prescriptions dispensed per patient per annum during the 5-year 
follow-up period.  Error bars indicate standard error. 
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